Service de Cardiologie Pédiatrique, Hôpital Sainte-Justine, Université de Montréal, Canada.
Catheter Cardiovasc Interv. 2013 Sep 1;82(3):474-9. doi: 10.1002/ccd.24361. Epub 2013 May 15.
Although effective, transcatheter closure of perimembranous ventricular septal defects (pmVSD) with the Amplatzer Membranous VSD Occluder (AGA Medical Corporation, MN) carries a substantial risk of complete heart block, prompting many to abandon this intervention. A newly designed Amplatzer device for pmVSD was modified, in part, to minimize this risk. After rigorous preclinical testing, we report the first human experience with the Amplatzer Membranous VSD Occluder 2 (AGA Medical Corporation) in two patients (a 5-year old with a 12-mm pmVSD and a 26-year-old male with a 8-mm defect). Both procedures were successful, with no adverse events at 7 and 4 weeks of follow-up, respectively. Herein, we discuss characteristics of the new device, potential advantages compared to the prior version, and main technical aspects related to the procedure.
尽管经导管膜周部室间隔缺损（pmVSD）封堵术（AGA 医疗公司，MN）效果显著，但会带来完全性心脏传导阻滞的高风险，促使许多人放弃这种介入治疗。一种新设计的用于 pmVSD 的 Amplatzer 装置经过部分改良，以降低这种风险。经过严格的临床前测试，我们报告了首例使用 Amplatzer 膜周部室间隔缺损封堵器 2 （AGA 医疗公司）的人体经验，用于治疗两名患者（一名 5 岁的 12mm pmVSD 患者和一名 26 岁的 8mm 缺陷男性患者）。两次手术均成功，分别在 7 周和 4 周的随访时无不良事件发生。在此，我们将讨论新装置的特点、与前一代产品相比的潜在优势，以及与手术相关的主要技术方面。
